23ANDME HOLDING CO -CLASS A (ME)

Company Profile

23andMe Holding Co. is a consumer genetics and research company, which engages in assisting people to access, understand, and benefit from the human genome. The company is headquartered in South San Francisco, California and currently employs 769 full-time employees. The company went IPO on 2020-10-06. The firm operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Therapeutics business segment focuses on the use of genetic insights from databases of genetic and phenotypic information to develop novel therapies to improve patients’ lives. The Therapeutics segment consists of out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates.

Company Info

23ANDME HOLDING CO -CLASS A

349 Oyster Point Boulevard

South San Francisco CALIFORNIA

P: 16509386300

CEO: Josh Bayliss

Employees: 769

Website: https://investors.23andme.com/